157 related articles for article (PubMed ID: 29656586)
21. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
22. Making the Best of Available Options for Optimal Sarcoma Treatment.
Le Cesne A
Oncology; 2018; 95 Suppl 1():11-20. PubMed ID: 30554197
[TBL] [Abstract][Full Text] [Related]
23. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Zhou DD; King D; Thomson K; Grimison P
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e526-e528. PubMed ID: 35297193
[No Abstract] [Full Text] [Related]
26. Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
Assi T; Cesne AL
Future Oncol; 2023 Sep; 19(28):1893-1896. PubMed ID: 37781755
[No Abstract] [Full Text] [Related]
27. Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?
Assi T; Cesne AL
Immunotherapy; 2023 Jan; 15(1):5-8. PubMed ID: 36628569
[No Abstract] [Full Text] [Related]
28. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
30. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
Blay JY; Italiano A; Ray-Coquard I; Le Cesne A; Duffaud F; Rios M; Collard O; Bertucci F; Bompas E; Isambert N; Chaigneau L; Cassier P; Bui B; Decanter G; Derbel O; Coindre JM; Zintl P; Badri N; Penel N
BMC Cancer; 2013 Feb; 13():64. PubMed ID: 23388156
[TBL] [Abstract][Full Text] [Related]
33. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
34. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
37. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Grignani G; Martín-Broto J; Schuler M; Reichardt P
Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
39. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic use of fluorescence in situ hybridization in expert review in a phase 2 study of trabectedin monotherapy in patients with advanced, translocation-related sarcoma.
Sugita S; Asanuma H; Hasegawa T
Diagn Pathol; 2016 Apr; 11():37. PubMed ID: 27068820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
